Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
14 Maio 2008 - 11:57AM
PR Newswire (US)
MISSISSAUGA, ON, May 14 /PRNewswire-FirstCall/ -- Vasogen Inc.
(NASDAQ:VSGND; TSX:VAS) today announced that its President and CEO,
Chris Waddick, will present a Company overview at the Rodman &
Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, at
12:30 p.m. local time (6:30 a.m. ET) on Monday, May 19, 2008. A
live webcast of the presentation can be accessed through Vasogen's
website at http://www.vasogen.com/. An archived replay will also be
available following the presentation. About Vasogen: Vasogen is a
biotechnology company engaged in the research and development of
therapies designed to target the destructive inflammatory process
associated with the development and progression of cardiovascular
and neurodegenerative disorders. Certain statements contained in
this press release, the upcoming presentation and webcast, or
elsewhere in our public documents constitute "forward-looking
statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995 and/or "forward-looking
information" under the Securities Act (Ontario). These statements
may include, without limitation, plans to advance the development
of the Celacade(TM) System or our VP Series of drugs including
VP015 and VP025, plans to fund our current activities, statements
concerning our partnering activities, health regulatory
submissions, strategy, future operations, future financial
position, future revenues and projected costs. In some cases, you
can identify forward-looking statements by terminology such as
"may", "will", "should", "expects", "plans", "anticipates",
"believes", "estimated", "predicts", "potential", "continue",
"intends", "could", or the negative of such terms or other
comparable terminology. We made a number of assumptions in the
preparation of these forward-looking statements, including
assumptions about the nature, size, and accessibility of the market
for Celacade in the treatment of chronic heart failure,
particularly in Europe, the regulatory approval process leading to
commercialization and the availability of capital on acceptable
terms to pursue the development of Celacade, and the feasibility of
additional trials. You should not place undue reliance on our
forward-looking statements which are subject to a multitude of
risks and uncertainties that could cause actual results, future
circumstances or events to differ materially from those projected.
These risks include, but are not limited to, the outcome of further
ongoing analysis of the ACCLAIM trial results, the requirement or
election to conduct additional clinical trials and the size and
design of any such trials, delays or setbacks in the regulatory
approval process, difficulties in the maintenance of existing
regulatory approvals, securing and maintaining corporate alliances,
the need for additional capital and the effect of capital market
conditions and other factors on capital availability, the potential
dilutive effects of any financing, risks associated with the
outcomes of our preclinical and clinical research and development
programs, the adequacy, timing, and results of our clinical trials,
competition, market acceptance of our products, the availability of
government and insurance reimbursements for our products, the
strength of intellectual property, reliance on partners,
subcontractors, and key personnel, losses due to fluctuations in
the U.S.-Canadian exchange rate, and other risks detailed from time
to time in our public disclosure documents or other filings with
the Canadian and U.S. securities commissions or other securities
regulatory bodies. Additional risks and uncertainties relating to
our Company and our business can be found in the "Risk Factors"
section of our Annual Information Form and Form 20-F for the year
ended November 30, 2007, as well as in our later public filings.
The forward-looking statements are made as of the date hereof, and
we disclaim any intention and have no obligation or responsibility,
except as required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. DATASOURCE: Vasogen Inc. CONTACT: Glenn Neumann,
Investor Relations, 2505 Meadowvale Blvd., Mississauga, ON, Canada,
L5N 5S2, tel: (905) 817-2004, fax: (905) 569-9231,
http://www.vasogen.com/,
Copyright